EGFR and non-small cell lung carcinoma: As for Osimertinib, it is an irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved by the FDA and EMA as therapy for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation [52,53].